V
Vaderis Therapeutics
A clinical stage biotechnology company focussed on the treatment of rare and orphan diseases caused by Vascular Malformations
About Vaderis Therapeutics
Vaderis Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for rare and orphan diseases caused by vascular malformations. The company’s primary focus is on Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that leads to abnormal blood vessel formation and can cause serious bleeding and complications. Vaderis is advancing VAD044, an oral medication designed to address both the symptoms of HHT and to reduce the formation of new vascular lesions. By targeting the underlying mechanisms of the disease, Vaderis aims to modify the progression of HHT, positioning itself as a pioneer in this therapeutic area.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Basel, Switzerland
- Employees
- 22
- Open positions
- None listed
- Dealroom signal
- 93.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Vaderis Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Aug 2026 | $152M | $608M | Omega Funds · Perceptive Advisors · Medicxi · EQT Life Sciences | ↗ |
| LATE VC✓Equity / VC | Jan 2020 | $17M | $66M | Medicxi | ↗ |
Growth signals
Latest recorded traffic for Vaderis Therapeutics is 1.3K monthly website visits, down 59.4% over the last three months. Vaderis Therapeutics's team grew 37.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
TCGX
Omega Funds
Perceptive Advisors
EQT Life Sciences
Droia Oncology Ventures- KMKalehua Capital Management
Series B and later1 investor entered at this stage
Medicxi
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vaderis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vaderis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.